The Lancet. Child & adolescent health最新文献

{"title":"Childhood verbal abuse by adults: young people speaking up.","authors":"Livvy Smith, Prathit Singh, Paddy Crump, Poppy Bilderbeck, Ethan Adonteng, Peter Fonagy","doi":"10.1016/S2352-4642(26)00073-8","DOIUrl":"https://doi.org/10.1016/S2352-4642(26)00073-8","url":null,"abstract":"","PeriodicalId":94246,"journal":{"name":"The Lancet. Child & adolescent health","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147825370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shared ownership with young people in health research.","authors":" The Lancet Child Adolescent Health","doi":"10.1016/s2352-4642(26)00102-1","DOIUrl":"https://doi.org/10.1016/s2352-4642(26)00102-1","url":null,"abstract":"","PeriodicalId":94246,"journal":{"name":"The Lancet. Child & adolescent health","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147751238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence estimates of sickle cell disease among children and adolescents in sub-Saharan Africa: a systematic review and modelling analysis","authors":"Davies Adeloye PhD FFPH, Asa Auta PhD, Boni Maxime Ale MD, Jacqueline Y Thompson PhD, Prof Igor Rudan PhD FRSE, Global Health Epidemiology Research Group (GHERG)","doi":"10.1016/s2352-4642(26)00048-9","DOIUrl":"https://doi.org/10.1016/s2352-4642(26)00048-9","url":null,"abstract":"There is a scarcity of data reporting on the burden of sickle cell disease across many African settings, particularly among children, who have the highest risk of preventable morbidity and mortality in the absence of early diagnosis and care. We aimed to estimate the prevalence of sickle cell disease and the absolute number of paediatric cases in sub-Saharan Africa to inform policy and service responses.","PeriodicalId":94246,"journal":{"name":"The Lancet. Child & adolescent health","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147726834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and co-occurrence of six autoimmune diseases in childhood: a population-based cohort study in Norway.","authors":"Ketil Størdal,Runar Almaas,Helga Sanner,Line Sletner,Lars C Stene","doi":"10.1016/s2352-4642(26)00008-8","DOIUrl":"https://doi.org/10.1016/s2352-4642(26)00008-8","url":null,"abstract":"BACKGROUNDAutoimmune diseases are among the most common chronic diseases in childhood. We aimed to determine the incidence and co-occurrence of type 1 diabetes, inflammatory bowel disease, juvenile idiopathic arthritis, coeliac disease, autoimmune thyroid disease, and autoimmune liver disease by age and individual-level sociodemographic factors.METHODSIn this nationwide, population-based cohort study, we linked individual-level data from the Medical Birth Registry of Norway, Statistics Norway, the Norwegian Prescription Drug Registry, and the Norwegian Patient Registry for all children born in Norway between Jan 1, 2004, and Dec 31, 2020, and who were alive and living in Norway until aged 18 years or until Dec 31, 2024. Cases of diagnosed autoimmune disease (type 1 diabetes, inflammatory bowel disease, juvenile idiopathic arthritis, coeliac disease, autoimmune thyroid disease, and autoimmune liver disease) were identified from ICD-10 codes recorded in the Norwegian Patient Registry. At least two independent diagnostic code registrations were required for valid disease outcomes. Using Cox regression, we examined hazard ratios of the six autoimmune diseases as a co-occurring disease, by primary diagnosis, by region of birth, maternal education, and household income.FINDINGSData availability allowed complete analysis of data for 793 772 individuals born between Jan 1, 2007, and Dec 31, 2019. During a mean follow-up from birth to age 11·1 years (range 4·01-17·99), 15 012 autoimmune disease diagnoses were recorded in a total of 14 278 individuals (incidence rate 162·8 [95% CI 160·1-165·5] per 100 000 person-years). 709 (5·0%) individuals received two or three distinct diagnoses of autoimmune diseases by age 18 years. Statistically significant co-occurrence was observed between all autoimmune diseases examined, except for between inflammatory bowel disease and type 1 diabetes and between inflammatory bowel disease and autoimmune thyroid disease. The incidence of a co-occurring autoimmune disease was highest among individuals with autoimmune liver disease (65 [41·4%] of 157 cases). We found regional variation in incidence, with higher incidence in northern Norway compared with southern Norway for juvenile idiopathic arthritis (adjusted hazard ratio [HR] 1·83 [95% CI 1·55-2·15]), inflammatory bowel disease (1·52 [1·27-1·82]), and type 1 diabetes (1·14 [1·02-1·28]). Higher maternal education was associated with a reduced incidence of type 1 diabetes (HR 0·90 [95% CI 0·81-1·00]) and autoimmune thyroid disease (0·84 [0·72-0·98]), and a higher incidence of coeliac disease (1·45 [1·34-1·58]). Higher household income was associated with a reduced incidence of autoimmune thyroid disease (HR 0·85 [95% CI 0·72-0·99]) and a higher incidence of coeliac disease (1·63 [1·50-1·76]).INTERPRETATIONIncreased awareness of the risk of co-occurring autoimmune diseases in childhood is warranted by patients, clinicians, and health systems. Regional and socioeconomic differenc","PeriodicalId":94246,"journal":{"name":"The Lancet. Child & adolescent health","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147719588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paediatric autoimmunity: from single entity to shared vulnerability.","authors":"Kirsten Minden,Tilmann Kallinich","doi":"10.1016/s2352-4642(26)00065-9","DOIUrl":"https://doi.org/10.1016/s2352-4642(26)00065-9","url":null,"abstract":"","PeriodicalId":94246,"journal":{"name":"The Lancet. Child & adolescent health","volume":"129 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147719589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A co-created, global action-oriented framework for adolescent nutrition","authors":"Sara Estecha-Querol PhD, Catharine A K Fleming PhD, Silvia Alayón MS, Cristina Álvarez Sánchez PhD, Milca J Cameseria, Emily C Keats PhD, Sarah H Kehoe PhD, Webster Isheanopa Makombe LLBs, Amanda Murungi Eunice MS, Marion L Roche PhD, Amir Ali Samnani PhD, Deepika Sharma MPH, Miriam Shindler MA, Kesso Gabrielle van Zutphen MSc, Stephanie V Wrottesley PhD, Natasha Lelijveld PhD","doi":"10.1016/s2352-4642(26)00012-x","DOIUrl":"https://doi.org/10.1016/s2352-4642(26)00012-x","url":null,"abstract":"Optimal nutrition during adolescence is fundamental for growth and development. Yet globally, adolescent populations have a triple burden of malnutrition: undernutrition, micronutrient deficiencies, and overweight or obesity. Although several frameworks on adolescent nutrition exist, none include actions across programming, policy, research, and advocacy, and none included youth advocates during the design process or as end users. We—the Global Adolescent Nutrition Network and youth partners from Act4Food—aimed to develop a global framework to guide actions and investments to improve adolescent nutrition. The framework was co-created with youth partners and experts using an integrated knowledge translation approach, including stakeholder workshops and a stakeholder survey to assess its use and acceptability and to inform framework finalisation. In this Health Policy, we present a framework that recommends actions to improve adolescent nutrition across four levels: (1) adolescents; (2) households, peers, schools, and communities; (3) national systems; and (4) global systems and planetary health. These actions can be tailored to different contexts and support the work of donors, government ministries, policy makers, UN agencies, non-governmental organisations, youth organisations, the private sector, civil society, and researchers. Key to this process was the contribution of young people to ground the framework in the experiences of adolescents and to enable agency and empower responsive change.","PeriodicalId":94246,"journal":{"name":"The Lancet. Child & adolescent health","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147680927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landmark verdicts against social media companies in the USA","authors":"Bryant Furlow","doi":"10.1016/s2352-4642(26)00096-9","DOIUrl":"https://doi.org/10.1016/s2352-4642(26)00096-9","url":null,"abstract":"","PeriodicalId":94246,"journal":{"name":"The Lancet. Child & adolescent health","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147680925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early discontinuation of empirical antibiotics versus extended treatment in children with cancer and high-risk febrile neutropenia in Denmark: an open-label, randomised controlled trial","authors":"Nadja H Vissing MD PhD, Torjus Skajaa MD PhD, Dorthe Grosen MD PhD, Prof Birgitte Klug Albertsen MD PhD, Bodil Als-Nielsen MD PhD, Prof Henrik Hasle MD PhD, Milos M Koch MSc, Annett H Rasmussen MD, Jesper S Brok MD PhD, Lisa Hjalgrim MD PhD, Paul Blanche PhD, Prof Kjeld Schmiegelow MD DrMedSci, Prof Ulrikka Nygaard MD DrMedSci","doi":"10.1016/s2352-4642(26)00039-8","DOIUrl":"https://doi.org/10.1016/s2352-4642(26)00039-8","url":null,"abstract":"Early discontinuation of empirical antibiotics in adults with high-risk febrile neutropenia based on clinical stability and defervescence, irrespective of neutrophil count, has been shown to reduce antibiotic exposure without compromising safety. We aimed to evaluate this approach in children with cancer, a population for which randomised trials in high-income settings are lacking.","PeriodicalId":94246,"journal":{"name":"The Lancet. Child & adolescent health","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147680926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Model-informed precision dosing: from a niche for pharmacologists to daily business of paediatricians?","authors":"Saskia N de Wildt","doi":"10.1016/s2352-4642(26)00018-0","DOIUrl":"https://doi.org/10.1016/s2352-4642(26)00018-0","url":null,"abstract":"","PeriodicalId":94246,"journal":{"name":"The Lancet. Child & adolescent health","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147666750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bedside model-informed precision dosing of vancomycin in severely ill neonates and children in Belgium (the BENEFICIAL trial): a multicentre, randomised controlled trial.","authors":"Pieter A De Cock,Roos Colman,Anne Smits,Fiammetta Piersigilli,Marleen Renard,An Van Damme,Alexander Clarysse,Evelyn Dhont,Sophie Vanhaesebrouck,Victoria Bordon,Lidvine Boland,Bram De Wilde,Anca Amza,Lieselot Vanlanduyt,Thi Van Anh Nguyen,Filip Cools,Jutte van der Werff Ten Bosch,Daphne Vens,Frank Derriks,Laurent Houtekie,Reiner Mauel,Dimitri Van der Linden,Petra Schelstraete, ","doi":"10.1016/s2352-4642(25)00385-2","DOIUrl":"https://doi.org/10.1016/s2352-4642(25)00385-2","url":null,"abstract":"BACKGROUNDVancomycin is widely used to treat serious Gram-positive infections but is difficult to dose given its narrow therapeutic index and risk of acute kidney injury at high doses. We aimed to study whether model-informed precision dosing (MIPD) of vancomycin, compared with standard-of-care therapeutic drug monitoring (TDM), increases pharmacokinetic and pharmacodynamic target attainment, is safe, and reduces vancomycin-associated acute kidney injury in children with severe illness.METHODSThe BENEFICIAL trial is a pragmatic, individually randomised, controlled superiority trial done in 14 paediatric or neonatal intensive care and haemato-oncology units in seven hospitals in Belgium. Critically ill patients younger than 18 years initiating intravenous vancomycin for suspected or confirmed Gram-positive infection were eligible. Key exclusion criteria were extracorporeal support, severe acute kidney injury, chronic kidney disease, and imminent death. The intervention combined the use of an MIPD dosing calculator for starting and follow-up doses, with extra sampling for TDM in the first hours of treatment compared with standard-of-care TDM. Patients were randomly assigned (1:1) to MIPD or standard-of-care TDM of vancomycin using stratified permuted blocks by ward type. Allocation occurred via a secure web interface; patients, families, and the biostatistician were masked, but treating physicians and pharmacist staff were not. The intervention used Bayesian software with early sampling to estimate AUC. The primary outcome was the proportion of patients with a 24-h AUC-to-MIC ratio of 400-600 mg·h/L, assuming a minimum inhibitory concentration of 1 mg/L, 24-48 h after treatment initiation. A key secondary outcome was the proportion of patients with new or worsening acute kidney injury or death. These outcomes were assessed in the intention-to-treat (ITT) population (all randomly assigned patients who provided informed consent). Safety was evaluated in all patients who received at least one dose of vancomycin. This trial is registered with ClinicalTrials.gov (NCT04666948) and the EU Clinical Trials register (EudraCT 2019-004538-40), and is closed to recruitment.FINDINGSBetween Dec 28, 2020, and Dec 14, 2023, 332 patients aged between 1 day and 18 years were randomly assigned, 165 to the standard-of-care group and 167 to the intervention group. 18 participants were excluded from the analysis when their deferred consent was not followed by informed consent; therefore 314 patients (179 male and 135 female) were included in the analysis. Target AUC-to-MIC ratio attainment at 24-48 h was found in 82 (53·9%) of 152 patients with available data in the standard-of-care group and 112 (71·8%) of 156 in the MIPD group (absolute difference 18·9% [1·7 to 34·7]). The proportion of patients with acute kidney injury or all-cause mortality was numerically but not significantly lower in the intervention group (26 [16·9%] of 154 vs 19 [12·4%] of 153; absolute differen","PeriodicalId":94246,"journal":{"name":"The Lancet. Child & adolescent health","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147666749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}